The Validity of MRI in Evaluation of Tumor Response to Neoadjuvant Chemotherapy in Locally Advanced Breast Cancer

Mahboobeh Abedi¹, Donya Farrokh¹, Fatemeh Homaei Shandiz², Azadeh Joulæe³, Robab Anbiaee⁴, Behrooz Zandi¹, Masoumeh Gity⁵, Hamid Reza Sayah¹, Mohammad Sadegh Abedi⁶

Abstract

**Background:** Physical Examination (PE) and breast MRI are two of the current methods which have usually used in diagnosis of primary breast cancer. Their accuracy in detection of: either complete response or presence of residual tumor, however, has not yet been established in patients who have been received Neoadjuvant Chemotherapy (NAC).

The purpose of this study was to evaluate the diagnostic accuracy of breast MRI in assessment of residual neoplastic tissue after NAC in patients with Locally Advanced Breast Cancer (LABC).

**Methods:** Twenty patients with LABC have undergone contrast-enhanced MRI before and after the NAC. Considering histology as the gold standard, the tumor sizes in MRI and PE have compared with the histology results. We have calculated for all below: the accuracy, sensitivity, specificity, Positive Predictive Value (PPV) and Negative Predictive Value (NPV) for each of MRI and physical examination, as well as Pearson’s correlation coefficients between the results of MRI and PE, and their histology results.

**Results:** We have found an accuracy of 85% for MRI with a sensitivity of 100%, a specificity of 50%, a PPV of 83.3%, and an NPV of 100%. In addition, the accuracy for PE was 70% with a sensitivity of 71.4%, a specificity of 66.6%, a PPV of 83.3%, and an NPV of 50%. In this study, the calculated Pearson’s correlation coefficient for MRI and histology was 0.817 (p<0.0001) versus 0.26 (p=0.26) for correlation between PE and histology.

**Conclusion:** MRI has higher sensitivity but less specificity than PE for detection of residual tumor after NAC in locally advanced breast carcinoma. Also, the tumor size that has measured by MRI had highly correlation with the histology.

**Keywords:** Locally advanced; Breast cancer; Magnetic Resonance Imaging (MRI); Neoadjuvant; Chemotherapy

Please cite this article as: Abedi M, Farrokh D, Homaei Shandiz F, Joulæe A, Anbiaee R, Zandi B, Gity M, Sayah HR, Abedi MS. The Validity of MRI in Evaluation of Tumor Response to Neoadjuvant Chemotherapy in Locally Advanced Breast Cancer. Iran J Cancer Prev.2013; 6(1):28-35.

**Introduction**

Locally Advanced Breast Cancer (LABC) represents about 30-60% of breast cancer population in low-resource countries. Nowadays the current treatment for LABC could be Neoadjuvant Chemotherapy (NAC) that has followed by locoregional therapy (surgery and/or radiotherapy) and subsequent postoperative systemic chemotherapy [1].

Several advantages could be achieved by NAC in LABC patients: tumor downstaging with higher chances for breast conserving surgery; evaluation of tumor sensitivity to the selected chemotherapeutic regimens; and early control of micrometastatic disease[2].Using NAC, we could even attained the complete elimination of invasive tumor, from the breast tissue and axillary lymph nodes before surgery in a number of patients [3],which is associated with improved disease-free and overall survival in these patients [4].
About 25-40% of locally advanced breast cancers have complete histopathologic response after neoadjuvant chemotherapy [5] and breast conserving surgery is possible in 10%-40% of LABC patients [1].

Meanwhile histopathological complete response is not predictable exactly by any of the current diagnostic modalities [5]. All of the diagnostic methods (physical examination, mammography, sonography, and MRI) have been associated with both false positive and false negative results. In spite of these limitations, there lative accuracy of these modalities should be defined as present basis for clinical practice that guided the treatment [6].

The purpose of this study was evaluation of diagnostic accuracy of breast MRI in assessment of residual neoplastic tissue after NAC locally advanced breast carcinoma. The gold standard was pathology after radical mastectomy or conservative surgery.

Materials and Methods
From August 2010 to April 2012, 20 patients with clinical and histopathologic diagnosis of locally advanced breast cancer that have scheduled for NAC before surgery, have participated in our study. Before the initiation, and after the completion of chemotherapy, each patient has fully evaluated clinically by both medical and surgical oncologists who were specialist in breast cancer treatment. A contrast-enhanced MR study from both breasts has performed within 1 week after the initiation of NAC for each patient. After the completion of neoadjuvant courses and before the surgery, MR study has repeated. This study has approved by the Ethics Committee of Mashad University of Medical Sciences and was in compliance with Helsinki Declaration. Written informed consent has been obtained from all patients.

MRI Technique
All MR examinations have performed on a 1.5-T system (Symphony, Siemens Healthcare, Erlangen, Germany) with a dedicated breast coil in prone position. For each patient an axially oriented Turbo Inversion Recovery Magnitude (TIRM) sequence (TR=70, TE=6010, TI=150, slice thickness=1.5mm, matrix size=256*256) followed by six series of axial three-dimensional (3D) Fast Low-Angle Shot(FLASH) T1-weighted sequence (TR=12, TE=5, flip angle=25, slice thickness=2.2mm, matrix size=512*512 with 80 s acquisition time per volume), once before the administration of contrast and five times after intravenous injection of 0.1mmol GD-DTPA/kg of body weight (Magnavist; Schering Berlin, Germany) have obtained. Also, a sagittally oriented fat-suppressed T1-weighted sequence (TR=31, TE=7, slice thickness=2mm, matrix size=256*256) has performed after 3D FLASH T1-weighted images. Semi-quantitative analysis of the enhancing areas has performed with creating signal intensity to time curves of the region of interest.

MRI Interpretation
MR images have assessed and the findings have reported based on criteria previously described for interpretation of breast imaging [7-9].

All MRI images have then reevaluated by one radiologist expert in breast imaging interpretation. The dimension of the abnormally enhancing lesion or lesions has measured and the maximum dimension has registered as the size of the tumor. If the lesion has consisted of multiple adjacent abnormalities, the maximum dimension has considered as a single measurement encompassing the lesions farthest apart. Also, the abnormally enhancing lesions have characterized as focal (single discrete mass) or decentralized (segmental, regional or diffuse).

Neoadjuvant Chemotherapy
Patients have undergone one of the following regimens: 10 patients have received 6 cycles of TAC (Taxotere=Docetaxel) 75mg/m2, Adriamycin 60 mg/m2, Cyclophosphamide 600 mg/m2) and 10 patients have received 4 cycles of AC (Adriamycin 60 mg/m2, Cyclophosphamide 600 mg/m2) followed by 4 cycles of Taxol (paclitaxel) 175 mg/m2.

Based on clinical and imaging findings, using the measurements have obtained with PE and MRI and according to the "Response Evaluation Criteria in Solid Tumors (RECIST)" [10], the responses to chemotherapy have classified into the following categories:

1- Responders
- Complete Response (CR): no clinical evidence of residual tumor
- Partial Response (PR): reduction in size of the tumor more than 30%
2- No Responders
- Stable Disease (SD): reduction in size of the tumor inferior than 30%
- Progressive Disease (PD): increase in size of tumor or presence of new lesions

Statistical Analysis
Histology has considered as the gold standard and the size of the tumor on MRI and clinical
The accuracy, sensitivity, specificity, PPV and NPV for each of MRI and PE has calculated. We also have calculated Pearson's correlation coefficients to determine the association between the size of the tumor on MRI and PE and that of histology.

Results

Twenty patients with mean (±SD) age of 44.7 ± 9.5, with maximum age of 64y and minimum age of 30y, have included in our study. The histology of the tumor was invasive ductal carcinoma in 19 patients and invasive lobular carcinoma in one patient.

The time interval between the performance of MRI after the completion of chemotherapy and final surgery was 2-30 days, except for one patient who had a delay of about 85 days to present herself for surgery.

The average post-chemotherapy tumor size has predicted by MRI and PE was 3.49 cm (SD= 3.5 cm, range= 0-16 cm) and 2.2 cm (SD=2.1 cm, range=0-6 cm), respectively, in comparison with the mean size at histopathology of 3.57 cm (SD=3.83 cm, range=0-16 cm).

The findings of MRI, PE and histopathologic assessment of all patients have provided in Table 1. The calculated Pearson's correlation coefficient for MRI and histology was 0.817 (95% Confidence Interval [CI] = 0.58 – 0.92) (P < 0.0001) versus 0.26 (95% Confidence Interval [CI] = -0.20- 0.62) (P =0.26) correlation between PE and histology.

Table 1. Physical examination and MRI findings before and after neoadjuvant chemotherapy, compared with pathologic results

| Patient No. | Distribution | Size of lesion (cm) | Final histologic result |
|-------------|--------------|---------------------|-------------------------|
|             |              | Before neoadjuvant chemotherapy | After neoadjuvant chemotherapy |
|             | Physical examination | MRI | Physical examination | MRI | Pathology |
| 1           | Focal        | 10         | 11         | 3         | 3.1       | 0 | Invasive ductal carcinoma |
| 2           | Focal        | 7          | 4.5        | 1.5       | 1         | 2 | Invasive ductal carcinoma |
| 3           | Focal        | 6          | 3.9        | 4         | 2         | 7 | Invasive ductal carcinoma |
| 4           | Decentralized| 0          | 10         | 0         | 5         | 7 | Invasive ductal carcinoma |
| 5           | Focal        | 6          | 4.7        | 4         | 3         | 7 | Invasive ductal carcinoma |
| 6           | Decentralized| 8          | 8          | 0         | 0         | 0 | Invasive ductal carcinoma |
| 7           | Decentralized| 10         | 8          | 3         | 4         | 7 | Invasive ductal carcinoma |
| 8           | Focal        | 8          | 4.5        | 0         | 4.5       | 0 | Invasive lobular carcinoma |
| 9           | Decentralized| 9          | 7          | 3         | 4.6       | 5 | Invasive ductal carcinoma |
| 10          | Decentralized| 11         | 8          | 0         | 0         | 0 | Invasive ductal carcinoma |
| 11          | Focal        | 8          | 5          | 2         | 3.5       | 5 | Invasive ductal carcinoma |
| 12          | Focal        | 6          | 1.8        | 4         | 1.5       | 0 | Invasive ductal carcinoma |
| 13          | Focal        | 8          | 6          | 0         | 1.5       | 3 | Invasive ductal carcinoma and DCIS |
| 14          | Focal        | 8          | 5          | 0         | 3         | 2 | Invasive ductal carcinoma |
| 15          | Decentralized| 10         | 6          | 0         | 0         | 0 | Invasive ductal carcinoma |
| 16          | Focal        | 11         | 3.7        | 5         | 2.5       | 2.5 | Invasive ductal carcinoma |
| 17          | Focal        | 12         | 12         | 4         | 16        | 16 | Invasive ductal carcinoma and DCIS |
| 18          | Decentralized| 9          | 9          | 5         | 8         | 3.5 | Invasive ductal carcinoma |
| 19          | Focal        | 12         | 5.5        | 6         | 4.5       | 5 | Invasive ductal carcinoma |
| 20          | Decentralized| 14         | 7          | 0         | 1.5       | 7 | Invasive ductal carcinoma |

Note.—Decentralized distribution includes: segmental, regional, or multicentric distribution.

a Based on MRI findings before treatment.
MRI could predict the residual tumor size from 1 cm, in 11 out of 20 patients, however, overestimation and underestimation the size of the tumor by more than 1 cm for one, then for five patients respectively. On PE in 7 out of 20 patients, the size of the tumor has precisely predicted from 1 cm, for 3 patients the size has overestimated and in 4 patients, it has underestimated.

In one case with significantly underestimated tumor size on MRI examination (Figure 1), MRI has demonstrated a 1.5 cm residual mass, but a 7 cm invasive ductal carcinoma has reported at pathology. This patient had an interval of about 85 days between the performance of MRI and breast surgery, so the discrepancy between the MRI and histopathologic findings might somehow be related to tumor regrowth during this delay. Two of the three patients with false-positive MRI examinations had areas of decentralized regional enhancement on MR images, and in one of them MRI has shown peripheral nodular enhancement at a mass margin of corresponding to the main primary tumor site.

According to RECIST criteria, in MRI complete response has seen in 3 (Figure 2), partial response in 13 (Figures 3), stable disease in 3 (Figure 4), and progressive disease in 1 of the patients. On PE, 8 patients had complete response, but 12 patients had partial ones.

Six patients (30%) had pathologic complete response to neoadjuvant chemotherapy. MRI has precisely shown complete response in 3 of them, however, for 3 patients MRI was falsely positive (Figure 5).

On PE, 4 out of the six patients with pathologic complete response had no palpable tumor, yet the 2 other patients had false-positive examination. PE has shown no palpable mass in 5 patients with pathologic result of residual tumoral mass, indeed in these 5 patients PE was falsely negative.

Table 2. Accuracy, Sensitivity, Specificity, PPV and NPV for each of MRI and physical examination

| Characteristic | Physical examination | MRI |
|---------------|----------------------|-----|
| Accuracy      | 70%                  | 85% |
| Sensitivity   | 71.4%                | 100%|
| Specificity   | 66.6%                | 50% |
| PPV           | 83.3%                | 83.3%|
| NPV           | 50%                  | 100%|

Figure 1. A 42-year-old woman with left breast invasive ductal carcinoma (tumor size underestimated by MRI)

A. Contrast-enhanced MRI before chemotherapy shows a 7-cm irregular mass in upper part of the breast. B. After completion of chemotherapy CE-MRI shows a 1.5-cm area of regional enhancement at the site of previous tumor. Pathology showed a 7 cm residual tumor.
Pre-operative or neoadjuvant chemotherapy has gained a real accepted and underlying role in treatment of stage II and III breast cancer [11]. Obviously the most significant effect of this treatment is its potential to clear the neoplastic tissue completely from the breast and axillary region. Complete response makes the conservative surgery feasible with an improved expected survival [12].

In recent years, determining the best diagnostic modality, which could precisely predict “the complete pathologic breast tumors response” to neoadjuvant chemotherapy, has reformed into a favorite research topic. However, there is still no general consensus on this issue and the results have been controversial. MRI has been stated as a superior modality in comparison to the others, in tumor response assessment by several authors [13-17].

**Figure 2.** A 48-year-old woman with left breast invasive ductal carcinoma, complete response to neoadjuvant chemotherapy and true-negative MRI

A. Contrast-enhanced T1-weighted MRI before chemotherapy shows a 8-cm area of regional enhancement at the central and lateral portion of the left breast. B. After completion of chemotherapy at CE-MRI there is no visible abnormal enhancement. At pathology there was complete response to chemotherapy.

**Figure 3.** A 30-year-old woman with the left breast invasive ductal carcinoma, partial response to neoadjuvant chemotherapy

A. Contrast-enhanced T1-weighted MRI before chemotherapy shows a retroareolar enhancing round mass measuring 4.7-cm in diameter. B. After completion of chemotherapy CE-MRI shows a 3-cm round mass at previous tumor site. Pathology showed a 4cm residual mass.
By meta-analysis assessment in thirty four studies, that have performed to assess the diagnostic validity of Diffusion-Weighted MR Imaging (DW-MRI) and Contrast-Enhanced MR Imaging (CE-MRI) for predicting the pathological response to NAC in breast cancer, Wu and associates (2012) have found a high sensitivity (93%) for DW-MRI and a high specificity (91%) for CE-MRI [18].

In another recent study, DCE-MRI and histopathological standards have reported highly correlated; a fact which has approved by MRI accuracy assessment for estimating the efficiency of NAC in 91 patients with locally advanced breast cancer [19].

In present study, the accuracy of MRI in tumor response prediction to NAC in 20 patients with locally advanced breast cancer has evaluated. An accuracy of 85% for MRI with a sensitivity of 100%, a specificity of 50%, a PPV of 82% and a NPV of 100% has touched. The accuracy, sensitivity, specificity, PPV, and NPV for PE were 70%, 71%, 66%, 83%, and 50% respectively.

In a similar study Croshaw et al has reported an accuracy of 84%, a sensitivity of 86%, a specificity of 79%, a PPV of 93% and a NPV of 65% for MRI.
In their study accuracy for PE was 57%, sensitivity was 50%, specificity was 82%, PPV was 91% and NPV was 31% [20]. The results of Croshaw et al study fairly corresponds to our findings, however, we have found a sensitivity of 100% and a NPV of 100% for MRI in detection of residual tumor, whereas in Croshaw’s study sensitivity has been 86% and NPV 65%. This difference might be related to small sample size which was one of these study limitations.

Despite the fact that, in present research MRI could show the residual tumor with a high sensitivity (100%) and an intermediate specificity (50%) due to some discrepancy between the MRI size measurement, and histologic reports, then we also have calculated a Pearson’s correlation coefficient, need to be calculated for assessing two results correlation.

The correlation between MRI and histology, then the correlation between PE and histology was 0.817 (P < 0.0001) and 0.26 (P = 0.269), respectively, which means that a good correlation exists between MRI and histology; however, it reveals an unfavorable correlation between PE and histology.

In contrast to our findings, Prati et al and Rosen and associates by assessment of the correlation coefficients between PE and pathology have reported correlation values of 0.655 and 0.61, respectively, [6, 21] which have higher coefficients than the one that has been achieved in this study.

Such a contrast could be attributed to differences about native size and breast tissue consistency between the patients groups in these studies, which made the PE unreliable in our population. The mean age of patients in present study was about 5 years younger than Prati’s et al study and the more compact texture of breast in younger patients might be associated with difficulty in physical examination.

In comparison with Positron Emission Tomography (PET) study, some investigators have shown that MRI is more efficient in evaluating complete pathologic response to neoadjuvant chemotherapy [22-24].

By applying a threshold SUV of 2.0, Dose-Schwarz and colleagues have shown that the sensitivity of FDG-PET was 32.9% (specificity, 87.5%) for detection of residual tumor, which increased to 57.5% (specificity, 62.5%) at a threshold SUV of 1.5 [22]. In comparison to these results, a higher sensitivity (100%) and a lower specificity (50%) for MRI has attained in the present study.

On the other hand, the sensitivity and NPV for PET in Park et al study have been 100% [25,26], which are comparable to the present study results for MRI (sensitivity and NPV of 100%).

Moreover, by meta-analysis of nineteen studies relating to accuracy of (18)F-FDG PET in predicting responses to neoadjuvant therapies, Wang and colleagues have reported a sensitivity of 84%, a specificity of 66%, a PPV of 50% and a NPV of 91% for PET imaging[25]. In present study, higher sensitivity, PPV and NPV have obtained for MRI (100%, 83.3% and 100%, respectively).

**Conclusion**

In conclusion, in our study MRI has shown a higher sensitivity but a lower specificity than PE in detection of residual tumor after NAC in locally advanced breast carcinoma. Although MRI has underestimated the size of the residual tumor in five of the patients, the overall correlation between the tumor sizes measured on MRI, and histopathology was high. According to the findings of present study, MRI has an NPV of 100% in pathologic complete response prediction, thus, one might conclude that breast conserving surgery could accomplish based on MRI results, however, due to the small sample size used in our study, such a conclusion must infer cautiously. Further studies with greater sample sizes need to validate these results.

**Acknowledgment**

We sincerely appreciate our colleagues Dr. Roham Salek, Dr. Ali Jangjoo and Dr. Fatemeh Tavakkoli for their helpful contribution to the data collection. This research project has supported by Mashad University of Medical Sciences Research Council. The results that have described in this paper, have formed a part of submitted thesis by Dr. Mahboobeh Abedi, resident of radiology, Mashad University of Medical Sciences, a postgraduate degree in Radiology.

**Conflict of Interest**

The authors indicate no potential conflict of interest.

**Authors’ Contribution**

Mahboobeh Abedi has contributed in data acquisition and manuscript drafting.

Donya Farrokh has contributed in data interpretation.

Fatemeh Homaei Shandiz has contributed in study conception and design.

Azadeh Jalae has participated in study design.

Robab Anbiaee has participated in data acquisition.
Behroz Zandi has contributed in data interpretation.

Masoumeh Gity has contributed in interpreting the MR images.

Hamid Reza Sayah has participated in MR imaging performance.

Mohammad Sadegh Abedi has participated in statistical analysis.

References

1. Valero V, Buzdar AU, Hortobagyi GN. Locally Advanced Breast Cancer. Oncologist. 1996; 1:8-17.
2. Székely B, Szemtronti G, Kukla J, Szász AM, Langmár Z, Dank M. Primary systemic therapy in breast cancer--an update for gynecologic oncologists. Eur J Gynaecol Oncol. 2011; 32(6):636-41.
3. Kuerer HM, Newman LA, Smith TL, Ames FC, Hunt KK, Dhingra K, et al. Clinical course of breast cancer patients with complete pathologic primary tumor and axillary lymph node response to doxorubicin-based neoadjuvant chemotherapy. J Clin Oncol. 1999 Feb; 17(2):460-9.
4. Mani S, Chen Y, Aリングhaus LR, Li X, Chakravarthy AB, Bhave SR, et al. Early prediction of the response of breast tumors to neoadjuvant chemotherapy using quantitative MRI and machine learning. AMIA Annu Symp Proc. 2011; 2011:868-77.
5. Franklin JM, Anderson EM, Gleeson FV. MRI features of the complete histopathological response of locally advanced rectal cancer to neoadjuvant chemoradiotherapy. ClinRadiol. 2012 Jun; 67(6):546-52.
6. Prati R, Minami CA, Gornbein JA, Debruhl N, Chung D, Chang HR. Accuracy of clinical evaluation of locally advanced breast cancer in patients receiving neoadjuvant chemotherapy. Cancer. 2009 Mar 15; 115(6):1194-202.
7. Harms SE. Technical report of the international working group on breast MRI. J MagnReson Imaging. 1999 Dec; 10(6):979.
8. Liberman I, Morris EA, Lee MJ, Kaplan JB, LaTrenta LR, Menell JH, et al. Breast lesions detected on MR imaging: features and positive predictive value. AJR Am J Roentgenol. 2002 Jul; 179(1):171-8.
9. Brown J, Smith RC, Lee CH. Incidental enhancing lesions found on MR imaging of the breast. AJR Am J Roentgenol. 2001 May; 176(5):1249-54.
10. Londero V, Bazzocchi M, Del Frate C, Puglisi F, Di Loreto C, Francescutti G, et al. Locally advanced breast cancer: comparison of mammography, sonography and MR imaging in evaluation of residual disease in women receiving neoadjuvant chemotherapy. EurRadiol. 2004 Aug; 14(8):1371-9.
11. Chagpar AB, Middleton LP, Sahin AA, Dempsey P, Buzdar AU, Mirza AN, et al. Accuracy of physical examination, ultrasonography, and mammography in predicting residual pathologic tumor size in patients treated with neoadjuvant chemotherapy. Ann Surg. 2006 Feb; 243(2):257-64.
12. Bhattacharyya M, Ryan D, Carpenter R, Vinnicombe S, Gallagher CJ. Using MRI to plan breast-conserving surgery following neoadjuvant chemotherapy for early breast cancer. Br J Cancer. 2008 Jan 29; 98(2):289-93.
13. Schlossbauer T, Reiser M, Hellerhoff K. Importance of mammography, sonography and MRI for surveillance of neoadjuvant chemotherapy for locally advanced breast cancer. Radiologe. 2010 Nov; 50(11):1008-13.
14. Wasif N, Garreau J, Terando A, Kirsch D, Mund DF, Giuliano AE. MRI versus ultrasonography and mammography for preoperative assessment of breast cancer. Am Surg. 2009 Oct; 75(10):970-5.
15. Balu-Maestro C, Chapellier C, Bleuse A, Chanalet I, Chauvel C, Largillier R. Imaging in evaluation of response to neoadjuvant breast cancer treatment benefits of MRI. Breast Cancer Res Treat. 2002 Mar; 72(2):145-52.
16. Abraham DC, Jones RC, Jones SE, Cheek JH, Peters GN, Knox SM, et al. Evaluation of neoadjuvant chemotherapeutic response of locally advanced breast cancer by magnetic resonance imaging. Cancer. 1996 Jul 1; 78(1):91-100.
17. Cocconi G, Di Blasio B, Alberti G, Bisogni G, Botti E, Peracchia G. Problems in evaluating response of primary breast cancer to systemic therapy. Breast Cancer Res Treat. 1984; 4(4):309-13.
18. Wu LM, Ju NJ, Gu HY, Hua J, Chen J, Xu JR. Can diffusion-weighted MR imaging and contrast-enhanced MR imaging precisely evaluate and predict pathological response to neoadjuvant chemotherapy in patients with breast cancer? Breast Cancer Res Treat. 2012 Apr; 13.
19. Liu YH, Ye JM, Xu L, Huang QY, Zhao JX, Duan XN, et al. Effectiveness of dynamic contrast-enhanced magnetic resonance imaging in evaluating clinical responses to neoadjuvant chemotherapy in breast cancer. Chin Med J (Engl). 2011 Jan; 124(2):194-8.
20. Croshaw R, Shapiro-Wright H, Svensson E, Erb K, Julian T. Accuracy of clinical examination, digital mammogram, ultrasound, and MRI in determining postneoadjuvant pathologic tumor response in operable breast cancer patients. Ann SurgOncol. 2011 Oct; 18(11):3160-3.
21. Rosen EL, Blackwell KL, Boker JA, Soo MS, Bentley RC, Yu D, et al. Accuracy of MRI in the detection of residual breast cancer after neoadjuvant chemotherapy. AJR Am J Roentgenol. 2003 Nov; 181(5):1275-S.
22. Dose-Schwarz J, Tilling R, Aivil-Sassen S, Mahner S, Lebeau A, Weber C, et al. Assessment of residual tumour by FDG-PET: conventional imaging and clinical examination following primary chemotherapy of locally advanced breast cancer. Br J Cancer. 2010 Jan 5; 102(1):35-41. Epub 2009 Nov 17.
23. Choi JH, Lim HI, Lee SK, Kim WY, Kim SM, Cho E. The role of PET CT to evaluate the response to neoadjuvant chemotherapy in advanced breast cancer: comparison with ultrasonography and magnetic resonance imaging. J SurgOncol. 2010 Oct 1; 102(5):392-7.
24. Park JS, Moon WK, Lyou CY, Cho N, Kang KW, Chung JK. The assessment of breast cancer response to neoadjuvant chemotherapy: comparison of magnetic resonance imaging and 18F-fluorodeoxyglucose positron emission tomography. ActaRadiol. 2011 Feb 1; 52(1):21-8.
25. Wang Y, Zhang C, Liu J, Huang G. Is 18F-FDG PET accurate to predict neoadjuvant therapy response in breast cancer? A meta-analysis. Breast Cancer Res Treat. 2012 Jan; 131(2):357-69. Epub 2011 Sep 30.